Mitochondrial respiratory chain complex enzyme activities of limbic structures and psychiatric diagnosis in temporal lobe epilepsy patients: Preliminary results

There was no association between mitochondrial enzymatic activities and Mfn1 content in the hippocampus (P>.35), suggesting that the analyzed mitochondrial activities were not related to variation in the mitochondrial mass of the analyzed tissue (data not shown). Because brain samples were homoge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CNS neuroscience & therapeutics 2017-08, Vol.23 (8), p.700-702
Hauptverfasser: Osório, Camila Moreira, Lin, Kátia, Guarnieri, Ricardo, Oliveira Thais, Maria Emília Rodrigues, Dresch Vascouto, Helena, Remor, Aline Pertile, Lopes, Mark William, Linhares, Marcelo Neves, Ben, Juliana, Paula Martins, Roberta, Hoeller, Alexandre Ademar, Wolf, Peter, Latini, Alexandra, Walz, Roger
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:There was no association between mitochondrial enzymatic activities and Mfn1 content in the hippocampus (P>.35), suggesting that the analyzed mitochondrial activities were not related to variation in the mitochondrial mass of the analyzed tissue (data not shown). Because brain samples were homogenated for the biochemical assays, we were unable to control for different histopathologic subtypes of hippocampal sclerosis. Clinical and demographic characteristics of MTLE‐HS patients according to their psychiatric diagnosis Variables Psychiatric diagnosis “P” All patients n=32 (100%) None n=17 (53.1%) Depression n=9 (28.1%) Anxiety n=06 (18.8%) Gender Female 19 (59.4) 7 (21.9) 9 (28.1) 3 (9.4) 0.01 Male 13 (40.6) 10 (31.2) 0 (0.0) 3 (9.4) Hand dominance Right 28 (87.5) 15 (46.9) 9 (28.1) 4 (12.5) 0.16 Nonright 4 (12.5) 2 (6.2) 0 (0.0) 2 (6.2) AED treatment Monotherapy 10 (31.2) 5 (15.6) 3 (9.4) 2 (6.2) 0.97 Polytherapy 22 (68.8) 12 (37.5) 6 (18.8) 4 (12.5) Side of HS Left 15 (46.9) 7 (21.9) 6 (18.8) 2 (6.2) 0.35 Right 17 (53.1) 10 (31.2) 3 (9.4) 4 (12.5) Dexamethasone Yes 20 (62.5) 11 (34.4) 6 (18.8) 3 (9.4) 0.78 No 12 (37.5) 6 (18.8) 3 (9.4) 3 (9.4) Mean (SD) Age (y) 36.7 (12.0) 36.2 (13.0) 41.3 (11.0) 31.2 (9.5) 0.24 Years of education 6.7 (3.1) 6.6 (3.6) 7.6 (2.4) 5.8 (2.2) 0.59 Disease duration (y) 24.8 (11.3) 24.1 (10.4) 28.2 (12.9) 21.9 (12.1) 0.50 Epilepsy onset age (y) 7.3 (8.0) 7.8 (10.1) 6.8 (6.1) 6.6 (4.2) 0.79 Monthly frequency of seizures 8.5 (8.4) 7.5 (7.7) 9.1 (9.6) 10.3 (9.8) 0.55 1AEDs antiepileptic drugs were as follows: carbamazepine (n=24), phenobarbital (n=10), diphenylhydantoin (n=3), oxcarbazepine (n=3), lamotrigine (n=4), topiramate (n=2), valproic acid (n=3). Mitochondrial enzyme activities in temporal lobe structures of MTLE‐HS patients according to their psychiatric diagnosis Biochemical variables Mean (SD) All patients n=32 (100%) Psychiatric diagnosis “P” Level None n=17 (53.1%) Depression n=09 (28.1%) Anxiety n=06 (18.8%) Neocortex Complex I 764 (116) 755 (125) 852 (92) 776 (115) 0.63 Complex II 1.5 (0.4) 1.5 (0.4) 1.8 (0.1) 1.7 (0.1) 0.41 SDH 2.0 (0.8) 2.0 (0.8) 2.0 (1.0) 2.8 (1.0) 0.16 Complex IV 4.4 (1.4) 4.1 (1.4) 5.4 (1.7) 4.7 (0.9) 0.49 Hippocampus Complex I 685 (75) 685 (79) 699 (86) 704 (66) 0.78 Complex II 1.0 (0.3) 1.1 (0.3) 1.0 (0.2) 1.2 (0.1) 0.14 SDH 2.4 (0.7) 2.3 (0.8) 2.9 (0.5) 2.7 (0.6) 0.55 Complex IV 3.2 (0.8) 3.3 (0.9) 3.1 (0.5) 3.4 (0.4) 0.94 Amygdala Complex I 751 (110) 756 (129) 741 (114) 772 (32) 0.90 Complex
ISSN:1755-5930
1755-5949
DOI:10.1111/cns.12715